Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)
Status:
Terminated
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Understanding what treatments may facilitate perioperative care of Veterans with
posttraumatic stress disorder (PTSD) is of great importance to the U.S. health care system.
Patients with PTSD are characterized by elevated central nervous system catecholamine
concentrations and exaggerated and prolonged adrenergic responses to stress stimuli. At
present, there are no data on the effects of perioperative beta blocker therapy in patients
with PTSD, despite the rising significance of PTSD in Veteran populations.
This prospective, double-blind study proposes to randomize 150 Veterans with PTSD scheduled
for orthopedic, thoracic or vascular surgery at the San Francisco VA Medical Center to either
a 14-day course of propranolol or placebo. This study will then follow these Veterans for a
one-year period to evaluate the effects of the intervention on Veterans' surgical outcomes.
The investigators hypothesize that patients with PTSD randomized to the propranolol group
will demonstrate a reduced incidence of perioperative and postoperative morbidity and
mortality.
Phase:
N/A
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Northern California Institute of Research and Education United States Department of Defense